Lipid-based Drug Delivery Systems Research Articles

Current Advances in Lipid-Based Drug Delivery Systems as Nanocarriers for the Management of Female Genital Tuberculosis

Current Advances in Lipid-Based Drug Delivery Systems as Nanocarriers for the Management of Female Genital Tuberculosis

New fluorogenic triacylglycerols as sensors for dynamic measurement of lipid oxidation.

Lipids are major constituents of food but are also highly relevant substructures of drugs and are increasingly applied for the development of lipid-based drug delivery systems. Lipids are prone to oxidative degradation, thus affecting the quality of food or medicines. Therefore, analytical methods or tools that enable the degree of lipid oxidation to be assessedare of utmost importance to guarantee food and drug safety. Herein, we report the design, synthesis and application of the first-in-class fluorogenic triacylglycerols that enable dynamic monitoring of lipid oxidation via straightforward fluorescence readout. Our fluorogenic triacylglycerols can be used in both aqueous and lipid-based environments. Furthermore, we showed that the sensitivity of our fluorescent tracers towards oxidation could be tuned by incorporating either saturated or unsaturated acyl chains in their triacylglycerol core structure. With this, we provide a first proofofprinciple for the applicability of fluorescently labelled triacylglycerols as tracers to monitor the dynamics of lipid oxidation, thus paving the way for novel discoveries in the area of lipid analytics.

Addressing overlooked design considerations for nanoemulsions.

Despite progress in genetic and molecular research, which has opened up a myriad of targeted therapeutic possibilities, the compromised solubility and absorption profile of therapeutic entities restrict their passage across lipid barriers compromising efficacy. Consequently, nanoemulsions accrued significance as futuristic, safe, and effective lipid-based drug delivery systems due to their inherent array of physicochemical properties and provide exquisite bioavailability, reduced toxicity, and improved solubility of hydrophobic entities based on size and surface area. However, a pronounced gap exists in understanding and addressing challenges that arise during design and development of nanoemulsions. In this context, we have attempted to reconsider overlooked aspects of nanoemulsion design, offering insight into its commercial viability.

Anti-cancer and anti-microbial drug encapsulated lipid vesicles as drug delivery systems: Calorimetric and spectroscopic study

Lipid-based drug delivery systems (DDS) have attracted considerable interest for their capacity to achieve controlled drug release and encapsulate a variety of drug molecules—hydrophobic, hydrophilic, and amphiphilic—enabling diverse therapeutic applications. The research focuses on the structural and functional aspects of lipid-based vesicles that encapsulate both anti-cancer and anti-microbial drugs. The study employs ultrasensitive isothermal titration calorimetry and differential scanning calorimetry to gain mechanistic insights into the partitioning of drugs in the lipid-based DDS, release mechanisms, and binding interactions with serum proteins after the release.The structural properties of 5-fluorouracil (5-FU) suggest that the drug can partition into the outer region of the bilayer, where it forms hydrogen bonds with the polar heads of the amphiphilic lipid chains. Kanamycin indicates strong partitioning into liposomes as it displays a binding constant of the order of 106. Erythromycin exhibits limited partitioning into the bilayer, as assessed by fitting ITC data using a sequential two-binding site model. The values of change in enthalpy and entropy reflect the interaction nature and desolvation process during the drug's partitioning into liposomes. Thermodynamic signatures and transition temperatures obtained from ITC and DSC studies indicate that no diffusion-based drug release occurs from DPPC and DSPC-based liposomes. The interaction heat between the released drug and carrier serum albumin protein is very low and shows no consistent pattern. This suggests that the drugs are stably encapsulated in the drug delivery system (DDS), with no significant leakage over time. Insights from such studies on the influence of drug molecule structure on its partitioning into various lipid vesicles and further release of the same drugs from it guide in criteria for developing improvised drug delivery systems.

Phytocompounds and lipid-based drug delivery system for neurodegenerative diseases

Across the annals of time, organic molecules sourced from nature have found innumerable uses within the realms of healthcare, pharmaceuticals, and the study of living organisms. This abundant source of natural compounds has exhibited immense promise in the cure of diverse ailments, mainly neurodegenerative diseases owing to their minimum toxic and adverse effects. However, different challenges exist with phytocompounds from plants such as poor permeation, poor solubility (water/lipid), unsteadiness under extremely acidic pH conditions, and lack of targeting specificity. Furthermore, as a result of the existence of blood-brain barrier membrane and inconvenient pharmacokinetics characteristics of phytocompounds, their passage into the brain is constrained. In order to address this issue and augment the transportation of medications into the brain at a therapeutically effective level, it is imperative to formulate an innovative and pragmatic strategy. Many papers have shown that nanoformulations containing phytocompounds (resveratrol, quercetin, ferulic acid, curcumin, berberine, etc.) effectively improved many neurodegenerative diseases such as Parkinson’s, Alzheimer’s and Huntington’s diseases. This study provides an overview of phytocompounds that are used in nanosized lipid drug delivery systems. These systems are categorized according to lipid types and preparation techniques used in the formulation. Some studies regarding these systems and phytocompounds are also summarized.

In Vitro Cytotoxicity and Pharmacokinetic Study for Bosutinib Solid Lipid Nanoparticles.

Bosutinib (BST) is a Biopharmaceutics Classification System Class II drug having very low solubility and high permeability. Low aqueous solubility and poor dissolution of BST lead to poor bioavailability, Thus, limited aqueous solubility is the bottleneck for the therapeutic outcome of BST. Animal data suggest that the absolute bioavailability of BST is about 14-34% due to an extensive first-pass effect. To overcome hepatic first-pass metabolism and to enhance oral bioavailability, lipid-based drug delivery systems such as solid lipid nanoparticles (SLNs) can be used. SLNs are submicron colloidal carriers having a size range of 50-1000 nm. These are prepared with physiological lipid and dispersed in water or aqueous surfactant solution. BST can be conveniently loaded into SLNs to improve the oral bioavailability by exploiting the intestinal lymphatic transport. An optimal system was evaluated for bioavailability study in rats compared with that of BST suspension (SUS). An in vitro cytotoxicity study was done by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay method through ATCC cell lines; the percent inhibition was more in SLN when compared with SUS. The pharmacokinetics of BST-SLNs after oral administration in male Wistar rats was studied. The bioavailability of BST was increased by 2.28 fold when compared with that of a BST SUS. The results are indicative of SLNs as suitable lipid-based carrier system for improving the oral bioavailability of BST.

A novel sodium caseinate lipid-based auto-emulsifying delivery system to increase resveratrol intestinal permeation: Characterization and in vitro assessment

In recent years, nutraceuticals have emerged as a promising strategy for maintaining health and represent a high-growth market in Italy and across Europe. However, the lack of strict regulations regarding formulation requirements and proof of efficacy raises serious concerns about their poor bioavailability and, consequently, their uncertain health benefits. An emblematic example is t-resveratrol (RES), a cardioprotective stilbene polyphenol that undergoes extensive metabolism in the intestine and liver, resulting in a bioavailability of <1 %.This manuscript describes a novel technological matrix developed with the primary goal of improving RES oral bioavailability. This technology can be classified as a lipid-based autoemulsifying drug delivery system (LIBADDS), in which RES is thoroughly solubilized in a hot liquid phase composed of lipids and surfactants, and the mixture is further adsorbed onto a powder composed of polysaccharides and sodium caseinate (NaC), along with inert excipients, and then compressed.In this study, NaC was used for the first time to trigger pancreatin-mediated hydrolysis of an enteric-coated tablet, allowing micellar delivery of RES to the small intestine. The RES-containing tablets were characterized via differential scanning calorimetry (DSC) and X-ray diffraction (PXRD). The digested formulation, with simulated gastric and enteric fluids, was dimensionally assessed via dynamic light scattering (DLS). Finally, calculations of the bioaccessible fraction, dissolution tests, and in vitro permeability experiments using Caco-2 cell monolayers were carried out to preliminarily define the overall efficiency and applicability of this new technology in improving RES intestinal permeability.

Efficacy and safety of sulforaphane-loaded emulsomes as tested on MCF7 and MCF10A cells

Abstract Objectives Sulforaphane is well-known for its anti-cancer properties particularly against breast, skin and prostate cancers. High sensitivity of sulforaphane to oxygen, heat, and alkaline conditions, as well as its poor oral bioavailability and water instability limit its use in medicine. In this study, we aim to overcome the prementioned limitations by encapsulating sulforaphane within a lipid-based drug delivery system, known as emulsome, and investigate the anti-cancer features of the attained formulation. Methods The stability and dispersity of the formulation were assessed sequentially by zeta sizer, scanning electron microscopy and confocal laser scanning microscopy. Cell culture studies were performed to evaluate the anticancer activity of the formulation. Results Sulforaphane-loaded emulsomes with an average particle size of 246.0±14.1 nm, an average zeta potential of −23.5±2.4 mV and a polydispersity index of around 0.38 were produced. Encapsulations up to 0.036 mg/mL sulforaphane concentration was achieved. When MCF7 breast cancer cells were treated with sulforaphane-loaded emulsomes, a significant decrease was observed in proliferation of the cells along 72 h. In control group, emulsomes were found safe as tested at same concentrations on MCF-10a healthy cells. Applied as dissolved in DMSO, free sulforaphane with an IC50 value of 1.2 µM was more effective against MCF7 cells than sulforaphane-loaded emulsome formulation having a IC50 value 21.1 µM. Conclusions Sulforaphane-loaded emulsomes were obtained as stable, moderately disperse suspensions. Delivery of the bioactive compound into the cells were achieved. Yet, its biological activity remained behind its free form.

Contemporary Nanoemulsion Research: Extensive Examination of Self-Nanoemulsifying Drug Delivery Systems

Abstract: The administration of new pharmaceutical compounds orally can pose certain challenges in terms of drug absorption, bioavailability, and pharmacokinetic profile. However, a widely recognized method for enhancing bioavailability involves lipid-based drug delivery systems. Lipid-based drug delivery systems (LBDDS) are the most favourable method for formulating medicines that have low solubility in water. Nanotechnology exerts a significant impact on the therapeutic efficacy of hydrophobic medicines and has emerged as a crucial method in the field of drug delivery research. Self-nanoemulsifying drug delivery systems (SNEDDs) are an important approach that combines the advantages of lipid-based drug delivery systems (LBDDS) and nanotechnology. SNEDDs are currently the favoured method for enhancing the formulation of pharmaceuticals that have low solubility in water. SNEDDs are homogenous mixtures that can self-emulsify spontaneously with gentle stirring, forming an oil-in-water emulsion that conveniently protects and creates a pathway for the lipophilic drug. The small particle size of &lt;200nm increases the solubilisation capacity of the drug by increasing its surface area. SNEDDs have demonstrated the ability to enhance the bioavailability of medicines that are not easily soluble in water. SNEDDs stand apart from other solubility enhancement approaches due to their inclusion of biodegradable components, their ease of large-scale manufacture, and their numerous potential for drug targeting. The aim of the present review was to provide basic knowledge about formulation, applications, and benefits of using SNEDDs. A detailed manuscript has been prepared by doing a literature survey on databases like Google Scholar, SCOPUS, and Pubmed to review the current state of nanotechnology applications, industrial developments, and challenges for using SNEDDS as a novel delivery system is provided in this manuscript.

PREPARATION OF LIPID-BASED FORMULATIONS USING LOCAL BEESWAX SOURCED FROM HONEYCOMBS

Solid lipids used in formulation of novel drug delivery systems in most developing countries are sourced from abroad and are quite expensive. Wax from honeycombs is readily available, and is even disposed as waste, but can be utilized as a solid lipid for the formulation of different lipid-based drug delivery systems. This study aims to formulate and compare the features of the solid lipid nanoparticle (SLNs) and nanostructured lipid carrier (NLCs) delivery systems of quinine hydrochloride made with local beeswax (that is beeswax from locally sources honeycomb waste) and other solid lipids sourced from abroad. Local beeswax was first purified by hot bath method. Solidified reverse micellar solutions (SRMS) were prepared by fusion method using Phospholipon®90H and either local beeswax, Softisan®154, foreign beeswax, or stearic acid, separately. SLNs and NLCs of quinine made with SRMS of each of these solid lipids were formulated using hot homogenization method. These SLNs and NLCs were characterized. The average particle size of SLNs and NLCs made with local beeswax was 93.60 ± 4.44 nm and 112.80 ± 3.89 nm, respectively, and was not significantly (p &gt; 0.05) different from the sizes of formulations made from other solid lipids (SLNs: 96.64 to 118.9 ± 4.13 nm and NLCs: 99.68 ± 6.75 to 117.30 ± 4.60 nm). The particles were monodispersed having PDI ranging from 0.281±0.054 to 0.308±0.055. Encapsulation efficiency and loading capacity were generally poor, especially among the SLN formulations. However, SLNs made with local beeswax and stearic acid were able to encapsulate quinine, whereas foreign beeswax and Softisan®154 had zero encapsulation. This study reveals that the features of the SLNs and NLCs made with local beeswax where highly comparable with those formulated with the imported solid lipids. Therefore, local beeswax can serve as a suitable affordable and available alternative to other imported solid lipids for formulating different lipid drug delivery systems.

Angiogenic lipid-based drug delivery system (PhytoSolve) for treatment of a thin endometrium in animal model

Impaired vascular growth resulting from reduced vascular endothelial growth factor (VEGF) in the epithelial tissue of the glands is a primary cause of thin endometrium. Inducing angiogenesis offers a possible therapeutic strategy for this condition. This study aimed to develop a novel drug delivery system using S75 lipoid loaded with VEGF for thin endometrium therapy. The formulation of PhytoSolve consisted of a combination of lipid S75, glycerol, and MCT oil, which was prepared utilizing a probe sonicator. Female NMRI mice (n=30) were divided into six groups: control, sham, thin endometrial model, VEGF treatment, PhytoSolve treatment, and VEGF/PhytoSolve treatment. A thin endometrial model was induced by injecting 95 % ethanol. After the treatment period, tissue samples were collected to assess the endometrial thickness—the mean particle size of the PhytoSolve formulation measured 67.57±7.07 nm. Approximately 40 % of the loaded VEGF was released within the first 24 hours, followed by a sustained release rate of 10–20 % daily. The PhytoSolve group containing VEGF exhibited significantly increased endometrial thickness compared to the VEGF group (P<0.05). S75 lipoid-based PhytoSolve loaded with VEGF effectively promoted blood vessel formation. The combination of PhytoSolve S75 and VEGF holds promise for developing a biocompatible drug delivery system with therapeutic potential for treating thin endometrium and various other biomedical applications.

Exploring novel type of lipid-bases drug delivery systems that contain one lipid and one water-soluble surfactant only

None of transitional lipid-based drug delivery systems (LBDDS) includes compositions containing one lipid and one water-soluble surfactant that form stable microemulsions. The conversion of liquid LBDDS to solid LBDDS has been limited by low drug loading. Previously, we have developed drug solid microemulsions containing one lipid and TPGS (a water-soluble surfactant) that achieved high drug loading and remarkably increased oral bioavailability. This study aimed to test if binary lipid systems (BLS), composed of one lipid and one water-soluble surfactant that form stable self-emulsifying microemulsions, is not an exclusive but widely applicable type of LBDDS for other lipids and surfactants and evaluate the influences of chemical structures of lipids and surfactants on microemulsions and solid microemulsions. We systemically identified new BLS by using a library of lipids and surfactants. Propylene glycol diesters and glycerol triesters were favorable for forming stable microemulsions with Tween 80, Cremophor EL, or TPGS. To the best of our knowledge, this is the first report exploring and confirming that the BLS is a new addition to traditional LBDDS, provides a promising option for researchers, and has the potential to increase drug loading to facilitate the development of solid microemulsions.

A Review: Surface Engineering of Lipid-Based Drug Delivery Systems.

This review explores the evolution of lipid-based nanoparticles (LBNPs) for drug delivery (DD). Herein, LBNPs are classified into liposomes and cell membrane-based nanoparticles (CMNPs), each with unique advantages and challenges. Conventional LBNPs possess drawbacks such as poor targeting, quick clearance, and limited biocompatibility. One of the possible alternatives to overcome these challenges is surface modification of nanoparticles (NPs) with materials such as polyethylene glycol (PEG), aptamers, antibody fragments, peptides, CD44, hyaluronic acid, folic acid, palmitic acid, and lactoferrin. Thus, the main focus of this review will be on the different surface modifications that enable LBNPs to have beneficial properties for DD, such as enhancing mass transport properties, immune evasion, improved stability, and targeting. Moreover, various CMNPs are explored used for DD derived from cells such as red blood cells (RBCs), platelets, leukocytes, cancer cells, and stem cells, highlighting their unique natural properties (e.g., biocompatibility and ability to evade the immune system). This discussion extends to the biomimicking of hybrid NPs accomplished through the surface coating of synthetic (mainly polymeric) NPs with different cell membranes. This review aims to provide a comprehensive resource for researchers on recent advances in the field of surface modification of LBNPs and CMNPs. Overall, this review provides valuable insights into the dynamic field of lipid-based DD systems.

Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy

BackgroundThe tumor microenvironment is profoundly heterogeneous particularly when comparing sites of metastases. Establishing the extent of this heterogeneity may provide guidance on how best to design lipid-based drug delivery systems to treat metastatic disease. Building on our previous research, the current study employs a murine model of metastatic cancer to explore the distribution of ~ 100 nm liposomes. MethodsFemale NCr nude mice were inoculated with a fluorescently labeled, Her2/neu-positive, trastuzumab-resistant breast cancer cell line, JIMT-1mkate, either in the mammary fat pad to create an orthotopic tumor (OT), or via intracardiac injection (IC) to establish tumors throughout the body. Animals were dosed with fluorescent and radio-labeled liposomes. In vivo and ex vivo fluorescent imaging was used to track liposome distribution over a period of 48 h. Liposome distribution in orthotopic tumors was compared to sites of tumor growth that arose following IC injection. ResultsA significant amount of inter-vessel heterogeneity for DiR distribution was observed, with most tumor blood vessels showing little to no presence of the DiR-labelled liposomes. Further, there was limited extravascular distribution of DiR liposomes in the perivascular regions around DiR-positive vessels. While all OT tumors contained at least some DiR-positive vessels, many metastases had very little or none. Despite the apparent limited distribution of liposomes within metastases, two liposomal drug formulations, Irinophore C and Doxil, showed similar efficacy for both the OT and IC JIMT-1mkate models. ConclusionThese findings suggest that liposomal formulations achieve therapeutic benefits through mechanisms that extend beyond the enhanced permeability and retention effect.

Development of Focused Ultrasound-Assisted Nanoplexes for RNA Delivery.

RNA-based therapeutics, including siRNA, have obtained recognition in recent years due to their potential to treat various chronic and rare diseases. However, there are still limitations to lipid-based drug delivery systems in the clinical use of RNA therapeutics due to the need for optimization in the design and the preparation process. In this study, we propose adaptive focused ultrasound (AFU) as a drug loading technique to protect RNA from degradation by encapsulating small RNA in nanoliposomes, which we term nanoplexes. The AFU method is non-invasive and isothermal, as nanoplexes are produced without direct contact with any external materials while maintaining precise temperature control according to the desired settings. The controllability of sample treatments can be effectively modulated, allowing for a wide range of ultrasound intensities to be applied. Importantly, the absence of co-solvents in the process eliminates the need for additional substances, thereby minimizing the potential for cross-contaminations. Since AFU is a non-invasive method, the entire process can be conducted under sterile conditions. A minimal volume (300 μL) is required for this process, and the treatment is speedy (10 min in this study). Our in vitro experiments with silencer CD44 siRNA, which performs as a model therapeutic drug in different mammalian cell lines, showed encouraging results (knockdown > 80%). To quantify gene silencing efficacy, we employed quantitative polymerase chain reaction (qPCR). Additionally, cryo-electron microscopy (cryo-EM) and atomic force microscopy (AFM) techniques were employed to capture images of nanoplexes. These images revealed the presence of individual nanoparticles measuring approximately 100-200 nm in contrast with the random distribution of clustered complexes observed in ultrasound-untreated samples of liposome nanoparticles and siRNA. AFU holds great potential as a standardized liposome processing and loading method because its process is fast, sterile, and does not require additional solvents.

Unravelling the interactions between small molecules and liposomal bilayers via molecular dynamics and thermodynamic modelling

Lipid-based drug delivery systems hold immense promise in addressing critical medical needs, from cancer and neurodegenerative diseases to infectious diseases. By encapsulating active pharmaceutical ingredients – ranging from small molecule drugs to proteins and nucleic acids – these nanocarriers enhance treatment efficacy and safety. However, their commercial success faces hurdles, such as the lack of a systematic design approach and the issues related to scalability and reproducibility.This work aims to provide insights into the drug-phospholipid interaction by combining molecular dynamic simulations and thermodynamic modelling techniques. In particular, we have made a connection between the structural properties of the drug-phospholipid system and the physicochemical performance of the drug-loaded liposomal nanoformulations. We have considered two prototypical drugs, felodipine (FEL) and naproxen (NPX), and one model hydrogenated soy phosphatidylcholine (HSPC) bilayer membrane. Molecular dynamic simulations revealed which regions within the phospholipid bilayers are most and least favoured by the drug molecules. NPX tends to reside at the water-phospholipid interface and is characterized by a lower free energy barrier for bilayer membrane permeation. Meanwhile, FEL prefers to sit within the hydrophobic tails of the phospholipids and is characterized by a higher free energy barrier for membrane permeation. Flory-Huggins thermodynamic modelling, small angle X-ray scattering, dynamic light scattering, TEM, and drug release studies of these liposomal nanoformulations confirmed this drug-phospholipid structural difference. The naproxen-phospholipid system has a lower free energy barrier for permeation, higher drug miscibility with the bilayer, larger liposomal nanoparticle size, and faster drug release in the aqueous medium than felodipine. We suggest that this combination of molecular dynamics and thermodynamics approach may offer a new tool for designing and developing lipid-based nanocarriers for unmet medical applications.

Lipid-based Nanocarrier Drug Delivery Approach for Biomedical Application

Abstract: The development of nanosized drug-carrier systems has been investigated over the past few decades using various techniques. The two main categories of these systems are polymeric nanoparticles and lipid nanoparticles (LNPs). The toxicological risk associated with lipid nanoparticles is significantly lower than the danger associated with polymeric nanoparticles due to the materials' natural and biological origins. Lipid-based drug delivery systems like Nanostructured lipid carriers (NLCs) and Solid Lipid Nanoparticles (SLNs) are well-established nanotechnology systems for preparing all major pharmaceuticals. These delivery systems can be scaled up with easy manufacturing procedures and are biocompatible. NLCs are the second generation of lipid-based nanocarriers (SLNs), formed by combining solid and liquid biocompatible lipids to form an unstructured matrix that provides high entrapment efficiency of active constituents. LNPs can promote the distribution of active pharmaceutical ingredients to the target site. Increasing the active drug concentration to target organ LNPs enhances the therapeutic effectiveness and reduces the side effects. This paper reviews the structure of SLNs and different NLCs, various steps involved in manufacturing lipid nanoparticles, excipients used in the formulation, and applications for targeted drug delivery.

Swelling kinetics of mixtures of soybean phosphatidylcholine and glycerol dioleate

Lipid-based drug delivery systems offer the potential to enhance bioavailability, reduce dosing frequency, and improve patient adherence. In aqueous environment, initially dry lipid depots take up water and form liquid crystalline phases. Variation of lipid composition, depot size and hydration-induced phase transitions will plausibly affect the diffusion in and out of the depot. Lipid depots of soybean phosphatidylcholine (SPC) and glycerol dioleate (GDO) mixtures were hydrated for varying time durations in a phosphate-buffered saline (PBS) buffer and then analyzed with Karl Fischer titration, magnetic resonance imaging (MRI) and gravimetrically. Mathematical modeling of the swelling process using diffusion equations, was used to estimate the parameters of diffusion. Both composition of lipid mixture and depot size affect swelling kinetics… The diffusion parameters obtained in Karl Fischer titration and MRI (with temporal and spatial resolution respectively) are in good agreement. Remarkably, the MRI results show a gradient of water content within the depot even after the end of diffusion process. Apparently contradicting the first Fick’s law in its classical form, these results find an explanation using the generalized Fick’s law that considers the gradient of chemical potential rather than concentration as the driving force of diffusion.

Lipid-Based Drug Delivery Systems: A Promising Approach for Overcoming Bioavailability and Solubility Challenges in Drug Development

Abstract: For an extended period, lipid-based drugs have been employed to enhance the effectiveness of medications. Nevertheless, the notion of using lipids as carriers for drugs remains a fascinating concept. Lipid-based drug delivery systems (LBDDS) represent a cutting-edge technology aimed at tackling the challenges associated with bioavailability and solubility of drugs that are not readily soluble in water. The primary objective of lipid-based medicine formulation is to increase its bioavailability. The use of lipids in medicine administration is a feasible concept even if it is no longer new. LBDDS is one of the newest techniques for resolving problems with low water-soluble medication solubility and bioavailability. Pharmaceuticals may be marketed successfully formulated using these formulations for parenteral, pulmonary, topical, or oral administration. This article functions as a comprehensive review of existing literature on LBDDS. It involves a thorough investigation across various databases, including PubMed, Scopus, and Web of Science, with the aim of identifying relevant research studies. LBDDS are an effective method for making poorly soluble medications (BCS Classes II &amp; IV) more soluble and more bioavailable. This review article aims to draw attention to the importance of distinguishing between SMEDDS and SNEDDS, as well as the roles played by the many components that are needed for creating LBDDS. It also provides motivation and guts to expand the use of LBDDS on a pilot and industrial scale. Medication delivery systems based on lipids provide a wide range of possible applications by improving the bioavailability of some poorly soluble medicines and enabling the creation of physiologically well-tolerated medication formulations. Comprehending the physicochemical properties of molecules, fatty excipients, and gastrointestinal digestion is crucial for the creation of these systems. In conclusion, these delivery methods seem to have a bright future.

Functionalized and Theranostic Lipidic and Tocosomal Drug Delivery Systems: Potentials and Limitations in Cancer Photodynamic Therapy.

Photodynamic therapy (PDT) is a multidisciplinary area, which involves photophysics and photochemical sciences and plays an important role in cancer diagnosis and treatment. PDT involves a photo-activable drug called photosensitizer (PS), a specific wavelength of light and cellular compounds to produce toxic oxygen species in a much-localized way to destroy malignant tumors. Despite the various benefits of PDT, some PS-related limitations hinder its use as an ideal treatment option for cancer. To address these limitations (e.g., poor bioavailability, weak permeability, hydrophobicity, and aggregation), lipid-based and vesicular drug delivery systems have been employed. These carrier systems possess the ability to enhance the bioavailability, permeability, and solubility of the drug. Furthermore, they tend to load hydrophobic and lipophilic compounds and can be employed for an efficient and targeted drug delivery. The purpose of this review is to highlight the precise idea of PDT, the limitations of PDT related to PS, and the application of lipidic and tocosomal carriers in PDT for the treatment of various types of cancers. Liposomes, nanoliposomes, solid lipid nanoparticles, vesicular phospholipid gels, exosomes, transferosomes, and tocosomes are presented as commonly-employed vesicular drug carriers. Moreover, the amalgamation of cell-based drug delivery systems (CBDDS) with PDT holds considerable potential as an encouraging avenue in cancer treatment, especially in the context of immunotherapy.